Novel chimeric gene promoters responsive to hypoxia and ionizing radiation

Gene Therapy

Volumn 9, Issue 20, 2002, Pages 1403-1411

  Greco, O ^a,d   Marples, B ^a   Dachs, G U ^a   Williams, K J ^b   Patterson, A V ^c   Scott, S D ^a,d  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

CArG element; GDEPT; HRE; HRP IAA; Radiotherapy

Indexed keywords

DNA; EARLY GROWTH RESPONSE FACTOR 1; ERYTHROPOIETIN; HORSERADISH PEROXIDASE; INDOLEACETIC ACID; PHOSPHOGLYCERATE KINASE; PLASMID VECTOR; REGULATOR PROTEIN; VASCULOTROPIN;

ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CARCINOMA CELL; CHIMERA; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; ENHANCER REGION; FEMALE; GENE EXPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; HYPOXIA; IONIZING RADIATION; MARKER GENE; PRIORITY JOURNAL; PROMOTER REGION; SUICIDE GENE THERAPY;

ANIMALS; ANOXIA; ENZYME PRECURSORS; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; MAMMARY NEOPLASMS, ANIMAL; PROMOTER REGIONS (GENETICS); RADIOTHERAPY; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

ARMORACIA RUSTICANA; MINK CELL FOCUS-FORMING VIRUS;

EID: 0036773458     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301823     Document Type: Article

References (51)

1. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-1416.
2. Dachs GU et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3: 515-520.
3. Ratcliffe PJ, O'Rourke JF, Maxwell PH, Pugh CW. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998; 201: 1153-1162.
4. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-5454.
5. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514.
6. O'Rourke JF et al. Hypoxia response elements. Oncol Res 1997; 9: 327-332.
7. Zhong H et al. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835.
8. Talks KL et al. The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-421.
9. Greco O, Patterson AV, Dachs GU. Can gene therapy overcome the problem of hypoxia in radiotherapy? J Radiat Res (Tokyo) 2000; 41: 201-212.
10. Greco O, Tozer GM, Dachs GU. Oxic and anoxic enhancement of radiation-mediated toxicity by horseradish peroxidase/indole-3-acetic acid gene therapy. Int J Radiat Biol 2002; 78:178-181.
11. Greco O. Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumour conditions. Mol Cancer Ther 2001; 1: 151-160.
12. Greco O et al. Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid. Cancer Gene Ther 2000; 7: 1414-1420.
13. Hallahan DE et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786-791.
14. Datta R et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci USA 1992; 89: 10149-10153.
15. Marples B et al. Development of synthetic promoters for radiation-mediated gene therapy. Gene Therapy 2000; 7: 511-517.
16. Scott SD et al. A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Therapy 2000; 7: 1121-1125.
17. Nettelbeck DM, Jerome V, Muller R. Gene therapy: designer promoters for tumour targeting. Trends Genet 2000; 16: 174-181.
18. Stackhouse MA, Buchsbaum DJ. Radiation to control gene expression. Gene Therapy 2000; 7: 1085-1086.
19. Nabel GJ. Development of optimized vectors for gene therapy. Proc Natl Acad Sci USA 1999; 96: 324-326.
20. Hernandez-Alcoceba R, Pihalja M, Nunez G, Clarke MF. Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther 2001; 8:298-307.
21. Modlich U, Pugh CW, Bicknell R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Therapy 2000; 7: 896-902.
22. Ido A et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res 2001; 61: 3016-3021.
23. Wosikowski K et al. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Differ 1995; 6: 1395-1403.
24. Kawasaki T et al. Abrogation of apoptosis induced by DNA-damaging agents in human bladder- cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Int J Cancer 1996; 68: 501-505.
25. Ebert BL, Firth JD, Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem 1995; 270: 29083-29089.
26. Muller JM et al. Hypoxia induces c-fos transcription via a mitogen-activated protein kinase-dependent pathway. J Biol Chem 1997; 272: 23435-23439.
27. Yan SF et al. Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem 1999; 274: 15030-15040.
28. Lo LW et al. Endothelial exposure to hypoxia induces Egr-1 expression involving PKCalpha-mediated Ras/Raf-1/ERK1/2 pathway. J Cell Physiol 2001; 188: 304-312.
29. Yan SF et al. Protein kinase C-beta and oxygen deprivation. A novel Egr-1-dependent pathway for fibrin deposition in hypoxemic vasculature. J Biol Chem 2000; 275: 11921-11928.
30. Datta R et al. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci USA 1993; 90: 2419-2422.
31. Gonzalez-Flecha B et al. Oxidative stress produced by suprahepatic occlusion and reperfusion. Hepatology 1993; 18: 881-889.
32. Chandel NS et al. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 1998; 95: 11715-11720.
33. 2 sensing. J Biol Chem 2000; 275: 25130-25138.
34. Bonventre JV et al. Localization of the protein product of the immediate early growth response gene, Egr-1, in the kidney after ischemia and reperfusion. Cell Regul 1991; 2: 251-260.
35. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Therapy 2000; 7: 493-498.
36. Ruan H et al. A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia 2001; 3: 255-263.
37. Gorski DH et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-3378.
38. Kuroki M et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996; 98: 1667-1675.
39. Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by H2O2 in rat heart endothelial cells. Free Radic Biol Med 1998; 25: 891-897.
40. Kosmidou I, Xagorari A, Roussos C, Papapetropoulos A. Reactive oxygen species stimulate VEGF production from C(2)C(12) skeletal myotubes through a PI3K/Akt pathway. Am J Physiol Lung Cell Mol Physiol 2001; 280: L585-L592.
41. Gleadle JM, Ebert BL, Ratcliffe PJ. Diphenylene iodonium inhibits the induction of erythropoietin and other mammalian genes by hypoxia. Implications for the mechanism of oxygen sensing. Eur J Biochem 1995; 234: 92-99.
42. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996; 271: 32253-32259.
43. Fandrey J et al. Cobalt chloride and desferrioxamine antagonize the inhibition of erythropoietin production by reactive oxygen species. Kidney Int 1997; 51: 492-496.
44. Binley K et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Therapy 1999; 6: 1721-1727.
45. Boast K et al. Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum Gene Ther 1999; 10: 2197-2208.
46. An WG et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 1998; 392: 405-408.
47. Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 1994; 91: 6496-6500.
48. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90: 4304-4308.
49. Connolly CN et al. Transport into and out of the Golgi complex studied by transfecting cells with cDNAs encoding horseradish peroxidase. J Cell Biol 1994; 127: 641-652.
50. Hart SL et al. Lipid-mediated enhancement of transfection by a nonviral integrin- targeting vector. Hum Gene Ther 1998; 9: 575-585.
51. Coralli C et al. Limitations of the reporter green fluorescent protein under simulated tumor conditions. Cancer Res 2001; 61:4784-4790.